LENZ Therapeutics (LENZ) Cash & Current Investments (2020 - 2026)

LENZ Therapeutics (LENZ) has reported Cash & Current Investments for 7 consecutive years, with $258.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 1015.84% year-over-year to $258.4 million; the TTM figure through Mar 2026 stood at $258.4 million (up 1015.84% YoY), while the FY2025 annual figure was $292.3 million, up 1342.12% from the prior year.
• Cash & Current Investments declined to $258.4 million in Q1 2026 per LENZ's latest filing, from $292.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $339.2 million in Q1 2022 and bottomed at $20.3 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $181.3 million across 5 years, with a median of $202.2 million in 2023.
• On a YoY basis, Cash & Current Investments climbed as much as 1342.12% in 2025 and fell as far as 88.45% in 2025.
• LENZ Therapeutics' Cash & Current Investments stood at $220.5 million in 2022, then sank by 70.16% to $65.8 million in 2023, then plunged by 69.19% to $20.3 million in 2024, then jumped by 1342.12% to $292.3 million in 2025, then retreated by 11.62% to $258.4 million in 2026.
• Business Quant data shows LENZ's Cash & Current Investments at $258.4 million in Q1 2026, $292.3 million in Q4 2025, and $202.2 million in Q3 2025.